Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Cinacalcet for K/DOQI Goals in ESRD
NCT00113945Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoints: bio-intact parathyroid hormone, Corrected serum calcium and 3 more. Started Jul 2003; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00113945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113945.